ArticleFrontiers in pediatrics2026
A single-center observational study of nirsevimab for prevention of RSV infection in preterm infants.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to evaluate the clinical efficacy of nirsevimab in preventing respiratory syncytial virus (RSV) infection in preterm infants, highlighting its potential to improve neonatal respiratory health. Methods: We conducted a retrospective cohort study involving preterm infants admitted to the Neonatology Department of Inner Mongolia Maternity and Child Health Care Hospital between November 2024 and January 2026. The immunization group included infants receiving nirsevimab, while the non-immunized group was matched via propensity score matching. Both groups received standard care. Clinical data, as well as diagnostic and therapeutic processes, were collected. The efficacy and safety of nirsevimab were evaluated, and the incidence and severity of RSV-associated respiratory infections in two groups were followed up (severe cases were defined as those requiring respiratory support or experiencing adverse outcomes). Results: (1) Compared with the non-immunized group, the efficacy rate of preventing RSV-associated respiratory infections was significantly higher in the nirsevimab immunized group (98.73% vs. 84.81%), with a statistically significant difference ( Conclusions: During the RSV epidemic season, our findings indicate that prophylactic treatment with nirsevimab significantly reduces the incidence of RSV infection in preterm infants, decreases the rehospitalization due to RSV infection in preterm infants, and demonstrates a favorable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.